Here, we explored the role of PLK1 in the sensitivity of cell lines of different tumor types to SN38 and evaluated pharmacological inhibition of PLK1 in preclinical models as an approach to enhance CPT11 antitumor activity and overcome drug resistance. Here, PLK1 is linked to neoplasm.